By Josh Beckerman

Sesen Bio Inc. said it is "deeply disappointed" after it received a Complete Response Letter from the U.S. Food and Drug Administration regarding its Biologics License Application for Vicineum.

The company's shares were recently halted.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

August 13, 2021 15:11 ET (19:11 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Sesen Bio (NASDAQ:SESN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Sesen Bio Charts.
Sesen Bio (NASDAQ:SESN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Sesen Bio Charts.